• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CSL (ASX:CSL) Faces Pressure To Rebuild Confidence, Is It Still Trading At A Discount?

    Simply Wall St·09/18/2026 12:30:19
    Listen to the news

    CSL (ASX:CSL) has put shareholder concerns front and centre after its board openly acknowledged frustration with the company’s weaker commercial and financial outcomes and pledged urgent investment in its core plasma operations to rebuild confidence.

    Recent trading tells a mixed story. CSL’s share price has climbed around 51% over the past 90 days and about 5% over the last month, yet the 1 year total shareholder return is down about 9% and the 5 year total shareholder return has declined roughly 39%. This suggests that the latest rebound is rebuilding momentum after a much tougher multi year stretch.

    Scan how CSL compares with other healthcare groups under pressure by running the hand picked 7 resilient stocks with low risk scores that highlights resilient balance sheets and steadier track records.

    CSL’s sharp 90 day rebound sits against multi year losses and a board that has called out underwhelming outcomes. Is this latest move a reset around the business, or another swing in sentiment ahead of what the valuation indicates next?

    Most Popular Narrative: 16% Undervalued

    CSL is priced at A$175.59 against a narrative fair value of A$210.00. This frames the recent share price rebound as only a partial catch up to what followers of the story think the business could justify over time.

    Future plans

    • Expand plasma collection centres to support growing demand.

    • Continue integrating and growing the acquired Vifor kidney-care business.

    • Invest heavily in new therapies for immunology, haematology and rare diseases.

    • Improve manufacturing capacity and operational efficiency.

    See why 37 investors see CSL as 16% undervalued.

    According to danmad, the narrative rests on CSL’s position in plasma therapies and vaccines, the regulatory protection around its products, and the idea that healthcare demand tends to hold up through different economic cycles, all assessed using a 7.50% discount rate.

    That lens matters when set against current fundamentals. The group generated A$15,797.0m of revenue but reported a net loss of A$2,579.0m, carries a high level of debt, and has a negative return on equity, while forecasts point to earnings growth of 44.47% per year and a move back into profitability over the next 3 years.

    On this narrative, the gap between the A$210.00 fair value and the A$175.59 share price reflects investors still wrestling with recent disappointments in execution and leverage, set against the long history of strong returns and the planned investment in plasma and new therapies.

    Result: Fair Value of A$210.00 (UNDERVALUED)

    Still, CSL’s narrative could easily be knocked off course if integration of CSL Vifor drags on profitability or if the high debt load constrains reinvestment.

    Find out about the key risks to this CSL narrative.

    Next Steps

    Sentiment around CSL is split. This is exactly why it can help to act promptly, review the underlying data yourself, and then weigh both the 3 key rewards and 1 important warning sign.

    Looking for more CSL investment ideas?

    If CSL has your attention, do not stop here. Broaden your watchlist with focused screeners so you are not missing opportunities sitting in plain sight.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.